CN101175477A - 碘塞罗宁的控释药物组合物及其制备和使用方法 - Google Patents

碘塞罗宁的控释药物组合物及其制备和使用方法 Download PDF

Info

Publication number
CN101175477A
CN101175477A CNA2006800163341A CN200680016334A CN101175477A CN 101175477 A CN101175477 A CN 101175477A CN A2006800163341 A CNA2006800163341 A CN A2006800163341A CN 200680016334 A CN200680016334 A CN 200680016334A CN 101175477 A CN101175477 A CN 101175477A
Authority
CN
China
Prior art keywords
pharmaceutical composition
liothyronine
release
pharmaceutically
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800163341A
Other languages
English (en)
Chinese (zh)
Inventor
马丁·维德·毕斯利
大卫·P·浩斯
欧文·克莱恩
查尔斯·L·潘普林
大卫·约翰·雷诺茨
凯文·H·希尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King Pharmaceuticals Research and Development Inc
Original Assignee
King Pharmaceuticals Research and Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Research and Development Inc filed Critical King Pharmaceuticals Research and Development Inc
Publication of CN101175477A publication Critical patent/CN101175477A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2006800163341A 2005-03-31 2006-03-31 碘塞罗宁的控释药物组合物及其制备和使用方法 Pending CN101175477A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66662105P 2005-03-31 2005-03-31
US60/666,621 2005-03-31

Publications (1)

Publication Number Publication Date
CN101175477A true CN101175477A (zh) 2008-05-07

Family

ID=37054215

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800163341A Pending CN101175477A (zh) 2005-03-31 2006-03-31 碘塞罗宁的控释药物组合物及其制备和使用方法

Country Status (11)

Country Link
US (1) US20060246133A1 (enExample)
EP (1) EP1863446A2 (enExample)
JP (1) JP2008534621A (enExample)
KR (1) KR20070119714A (enExample)
CN (1) CN101175477A (enExample)
AU (1) AU2006230557A1 (enExample)
BR (1) BRPI0609779A2 (enExample)
CA (1) CA2603313A1 (enExample)
IL (1) IL185723A0 (enExample)
MX (1) MX2007011826A (enExample)
WO (1) WO2006105482A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987358A (zh) * 2011-11-14 2014-08-13 阿尔特刚股份有限公司 甲状腺激素t3和/或t4的单次剂量药物制剂
CN115645361A (zh) * 2022-09-30 2023-01-31 天津市眼科医院 一种用于加强角膜生物力学性质的眼用制剂及t3的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
WO2008057464A2 (en) * 2006-11-01 2008-05-15 King Pharmaceuticals Research And Development, Inc. Compositions and methods for improving the bioavailability of liothyronine
ATE553753T1 (de) * 2007-02-16 2012-05-15 Suisse Electronique Microtech Überprüfungsverfahren
KR20180132955A (ko) * 2016-05-03 2018-12-12 스펙트릭스 테라퓨틱스, 엘엘씨 갑상샘 호르몬 또는 이의 유사체를 제공하는 조성물 및 방법
US10695309B2 (en) * 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
US11964048B2 (en) * 2020-12-18 2024-04-23 Amneal Complex Products Research Llc Sustained release compositions comprising liothyronine
EP4511009A1 (en) * 2022-04-22 2025-02-26 Prolevi Bio AB Compositions for modified release of active ingredients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
EP0550108B1 (en) * 1991-12-30 1998-03-18 Akzo Nobel N.V. Sustained release thyroactive composition
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987358A (zh) * 2011-11-14 2014-08-13 阿尔特刚股份有限公司 甲状腺激素t3和/或t4的单次剂量药物制剂
CN103987358B (zh) * 2011-11-14 2017-04-26 阿尔特刚股份有限公司 甲状腺激素t3和/或t4的单次剂量药物制剂
CN115645361A (zh) * 2022-09-30 2023-01-31 天津市眼科医院 一种用于加强角膜生物力学性质的眼用制剂及t3的应用
CN115645361B (zh) * 2022-09-30 2023-11-21 天津市眼科医院 一种用于加强角膜生物力学性质的眼用制剂及t3的应用

Also Published As

Publication number Publication date
US20060246133A1 (en) 2006-11-02
AU2006230557A1 (en) 2006-10-05
BRPI0609779A2 (pt) 2011-10-18
KR20070119714A (ko) 2007-12-20
JP2008534621A (ja) 2008-08-28
CA2603313A1 (en) 2006-10-05
WO2006105482A2 (en) 2006-10-05
IL185723A0 (en) 2008-01-06
WO2006105482A3 (en) 2006-12-07
MX2007011826A (es) 2007-11-22
EP1863446A2 (en) 2007-12-12

Similar Documents

Publication Publication Date Title
US7674479B2 (en) Sustained-release bupropion and bupropion/mecamylamine tablets
CN102946869B (zh) γ-羟基丁酸的速释制剂及剂型
US8318203B2 (en) Form of administration of racecadotril
PT1789021E (pt) Formulação de comprimidos de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável
KR20100129776A (ko) 왁스를 포함하는 서방형 제형
US20040156898A1 (en) Controlled release formulation of divalproex sodium
US20080026060A1 (en) Controlled-release pharmaceutical tablets
WO2019036712A1 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME OR ADENOMYOSIS
US20030147957A1 (en) Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
EP3668515A1 (en) Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
US6720004B2 (en) Controlled release formulation of divalproex sodium
US20230285342A1 (en) Compositions and methods
CN101175477A (zh) 碘塞罗宁的控释药物组合物及其制备和使用方法
US20220362191A1 (en) Compositions and methods
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
US20180064669A1 (en) Compositions and methods of providing thyroid hormone or analogs thereof
WO2014031161A1 (en) Chemical compositions
AU2017261225B2 (en) Compositions and methods of providing thyroid hormone or analogs thereof
WO2022157357A1 (en) Prolonged-release furazidin composition
EP1219295A1 (en) Controlled release formulation of valproate
WO2019094292A1 (en) Compositions and methods of providing thyroid hormone of analogs thereof
US20020031549A1 (en) Controlled release formulation of divalproex sodium
KR20160141044A (ko) 실데나필 제어방출성 경구제제
EP3452077A1 (en) Compositions and methods of providing thyroid hormone or analogs thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication